loading.........
 

Ellis Martin Report: Zhittya Genesis Medicine's FGF-1 is approved for Phase 1 Clinical Trials in Mexico for Parkinson's Disease

Zhittya Genesis Medicine Phase 1
Zhittya Genesis Medicine Phase 1
Malibu, CA, Feb 18, 2020 AEST (ABN Newswire) - In this segment of The Ellis Martin Report, Ellis will speak with Zhittya Genesis Medicine's CEO Dan Montano. We will discuss the approval of Zhittya's Phase I in Parkinson's to take place in Monterey, Mexico. Dr. Jack Jacobs Mr. Montano will be presenting at the "Traders Expo" in New York City March 8-9, 2020 with their booth being listed as #94. Dr. Jacobs will give two presentations on the title "Heart Disease, Strokes, Diabetes, Parkinson's, Alzheimer's and Multiple Sclerosis: in Therapeutic Angiogenesis a Treatment?

About Zhittya Genesis Medicine

Zhittya Genesis Medicine is a biotechnology company based in Las Vegas, Nevada. For 21 years our management has expended over $140 million dollars advancing this medicine. We are striving to change the world with our revolutionary new biological drug: FGF-1. In many trials FGF-1 has had the ability to grow new blood vessels in ischemic parts of the human body. These trials have shown that FGF-1 can reverse the progression of heart disease and completely heal diabetic foot ulcers.

To view the interview, please visit:
https://www.abnnewswire.net/press/en/100304/emr


About The Ellis Martin Report

Ellis Martin ReportThe Ellis Martin Report (TEMR) is an internet based radio program showcasing potentially undervalued companies to an audience of potential retail investors and fund managers that comprise our listening audience. TEMR is broadcasted on the VoiceAmerica Business Channel and The Opportunity Radio Network. CEO and company interviews are paid for by those represented on the program.

     


Contact

Dan Montano
Zhittya Genesis Medicine
1120 N Town Center Dr, Las Vegas, NV 89144 USA
E-mail: questions@zhittyamedicine.com
Phone: 702-802-9855
www.zgm.care


Related Companies

The Ellis Martin Report

ABN Newswire This Page Viewed:  (Last 7 Days: 119) (Last 30 Days: 727) (Since Published: 1811)